Professor Julia Scarisbrick MBhons ChB FRCP MD

Department of Immunology and Immunotherapy
Honorary Professor of Dermatology

Contact details

Telephone: +44 (0)121 372 5127 (PA Lynne Cook)
Email: julia.scarisbrick@uhb.nhs.uk

Address: Institute of Immunology and Immunotherapy
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Biography

Julia is a consultant dermatologist and leads the Cutaneous Lymphoma Service within the Rare Diseases Centre at University Hospital Birmingham and is Honorary Professor at the Institute of Immunology and Immunotherapy, University of Birmingham, UK. She is Chair of the EORTC Cutaneous Lymphoma Taskforce, Chair and Trustee of the UK Photopheresis Society and treasurer of both the UKCLG and International Society of Cutaneous Lymphomas (ISCL).

Julia is active in both clinical and molecular research fields for cutaneous lymphoma. She has a successful translational research program and is involved in the development and delivery of both commercial and academic clinical studies. She has published over 100 peer-reviewed articles, contributed to a number of books, and is involved in the development of management guidelines.

Research

Julia gained a higher medical degree from University of London for her thesis on ‘Molecular genetics of cutaneous T-cell lymphoma’. She is an academic with a specialist interest in cutaneous lymphoma for which she is internationally renowned. She is Chief Investigator for a number of clinical studies developing treatments for CTCL and has a highly successful translational research program. Her research interests include developing a prognostic index for skin lymphoma (PROCLIPI STUDY) to stratify patients allowing best management for improved survival and quality of life.

Publications

Recent publications

Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.17117. Epub ahead of print. PMID: 33095448.

Knobler R, Arenberger P, Arun A, Assaf C, Bagot M, Berlin G, Bohbot A, Calzavara-Pinton P, Child F, Cho A, French LE, Gennery AR, Gniadecki R, Gollnick HPM, Guenova E, Jaksch P, Jantschitsch C, Klemke C, Ludvigsson J, Papadavid E, Scarisbrick J, Schwarz T, Stadler R, Wolf P, Zic J, Zouboulis C, Zuckermann A, Greinix H. European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1. J Eur Acad Dermatol Venereol. 2020 Oct 6. doi: 10.1111/jdv.16890. Epub ahead of print. PMID: 33025659.

Knobler R, Arenberger P, Arun A, Assaf C, Bagot M, Berlin G, Bohbot A, Calzavara-Pinton P, Child F, Cho A, French LE, Gennery AR, Gniadecki R, Gollnick HPM, Guenova E, Jaksch P, Jantschitsch C, Klemke C, Ludvigsson J, Papadavid E, Scarisbrick J, Schwarz T, Stadler R, Wolf P, Zic J, Zouboulis C, Zuckermann A, Greinix H. European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 - Part 2. J Eur Acad Dermatol Venereol. 2020 Sep 22. doi: 10.1111/jdv.16889. Epub ahead of print. PMID: 32964529.

Kinsella FAM, Bencito A, Kulik D, Hurst E, Gilleece M, Snowden JA, Malladi R, Scarisbrick J, Gennery A, Alfred A. UK national audit of extracorporeal photopheresis (ECP) in chronic graft versus host disease. Leuk Lymphoma. 2020 Sep 2:1-4. doi: 10.1080/10428194.2020.1815015. Epub ahead of print. PMID: 32876511.

Campbell BA, Scarisbrick JJ, Kim YH, Wilcox RA, McCormack C, Prince HM. Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. Cancers (Basel). 2020 Aug 17;12(8):2311. doi: 10.3390/cancers12082311. PMID: 32824427; PMCID: PMC7463470.

Hodak E, Sherman S, Papadavid E, Bagot M, Querfeld C, Quaglino P, Prince HM, Ortiz-Romero PL, Stadler R, Knobler R, Guenova E, Estrach T, Patsatsi A, Leshem YA, Prague-Naveh H, Berti E, Alberti-Violetti S, Cowan R, Jonak C, Nikolaou V, Mitteldorf C, Akilov O, Geskin L, Matin R, Beylot-Barry M, Vakeva L, Sanches JA, Servitje O, Weatherhead S, Wobser M, Yoo J, Bayne M, Bates A, Dunnill G, Marschalko M, Buschots AM, Wehkamp U, Evison F, Hong E, Amitay-Laish I, Stranzenbach R, Vermeer M, Willemze R, Kempf W, Cerroni L, Whittaker S, Kim YH, Scarisbrick JJ; Cutaneous Lymphoma International Consortium (CLIC) institutions. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study. Br J Dermatol. 2020 Jun 23. doi: 10.1111/bjd.19303. Epub ahead of print. PMID: 32574377.

Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown L, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Huen A, Walewski J, Wang Y, Lisano J, Richhariya A, Feliciano J, Zhu Y, Bunn V, Little M, Zagadailov E, Dalal MR, Duvic M. Patient- reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Eur J Cancer. 2020 Jul;133:120-130. doi: 10.1016/j.ejca.2020.04.010. Epub 2020 Jun 2. PMID: 32502876.

Quaglino P, Prince HM, Cowan R, Vermeer M, Papadavid L, Bagot M, Servitjie O, Berti E, Guenova E, Stadler R, Querfeld C, Busschots AM, Hodak E, Patsatsi A, Sanches J, Maule M, Yoo J, Kevin M, Fava P, Ribero S, Zocchi L, Rubatto M, Fierro MT, Wehkamp U, Marshalko M, Mitteldorf C, Akilov O, Ortiz-Romero P, Estrach T, Vakeva L, Enz PA, Wobser M, Bayne M, Jonak C, Rubeta M, Forbes A, Bates A, Battistella M, Amel-Kashipaz R, Vydianath B, Combalia A, Georgiou E, Hauben E, Hong EK, Jost M, Knobler R, Amitay-Laish I, Miyashiro D, Cury-Martins J, Martinez X, Muniesa C, Prag-Naveh H, Nikolaou V, Quint K, Ram-Wolff C, Rieger K, Stranzenbach R, Szepesi Á, Alberti-Violetti S, Felicity E, Cerroni L, Kempf W, Whittaker S, Willemze R, Kim Y, Scarisbrick JJ. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Study (PROCLIPI study). Br J Dermatol. 2020 Jun 1. doi: 10.1111/bjd.19252. Epub ahead of print. PMID: 32479678.

Saulite I, Ignatova D, Chang YT, Fassnacht C, Dimitriou F, Varypataki E, Anzengruber F, Nägeli M, Cozzio A, Dummer R, Scarisbrick J, Pascolo S, Hoetzenecker W, Bobrowicz M, Guenova E. Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. Oncoimmunology. 2020 Mar 18;9(1):1738797. doi: 10.1080/2162402X.2020.1738797. PMID: 32760603; PMCID: PMC7386859.

Scarisbrick JJ. Survival in Mycosis Fungoides and Sezary Syndrome: How Can We Predict Outcome? J Invest Dermatol. 2020 Feb;140(2):281-283. doi: 10.1016/j.jid.2019.08.440. PMID: 31980062.

View Julia Scarisbrick full list of publications.